Zai Lab Limited — Company profile
Healthcare · Biotechnology · China
Last price 22.36 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.78B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.
Details
| Name | Zai Lab Limited |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 1784 |
| Founded | 2013 |
| Ipo Date | 2017-09-20 |
| Ceo | Ying Du |
| Country | China |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US98887Q1040 |
| Cusip | 98887Q104 |
| Cik | 0001704292 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Dr. Ying Du Ph.D. | Founder, Chairperson and Chief Executive Officer |
| Dr. Rafael G. Amado M.D. | President and Head of Global Research and Development |
| Dr. Yajing Chen Ph.D. | Chief Financial Officer |
| Frazor Titus Edmondson III, J.D. | Chief Legal Officer and Corporate Secretary |
| Christine Chiou | Senior Vice President and Head of Investor Relations |
Contact
| Address | Building B, 899 Halei Road, Pudong, 201203, China |
| Phone | 86 21 6163 2588 |
| Website | https://www.zailaboratory.com |